Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cellact Pharma GmbH manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This 1 action is assigned to 1 distinct examiner, MACH, ANDRE, who is also the busiest examiner with 1 busiest examiner pending action. Because the busiest examiner pending count matches the total pending office actions at 1, there is no distribution of labor across different personnel.
The prosecution is currently located in 1 distinct art unit, reflecting the technical scope for the pending filing. Practitioners should note that MACH, ANDRE has oversight of the pending workload, meaning the outcome of this 1 action will dictate the immediate success rate for the portfolio in the Biotechnology & Pharmaceuticals area. This concentration allows for a focus on the specific requirements and examination style of this individual. The presence of 1 pending office action represents the current scale of engagement with the patent office. Practitioners can tailor their approach specifically to MACH, ANDRE without needing to coordinate across multiple art units or examiner preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022353 | ETOPOSIDE TONIRIBATE FORMULATION | MACH, ANDRE | 28d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022353 | ETOPOSIDE TONIRIBATE FORMULATION | MACH, ANDRE | 1615 | §103 | Non-Final OA | 28d overdue | Pending | Feb 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial